precision medicine

Research in Review

Surgery Improves Survival in Patients With Renal Cancer

06/21/2016

JCP Editors

Surgery may improve survival for patients who receive targeted therapies for metastatic renal cell cancer, according to a study by researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital (Boston,...

...

06/21/2016

Journal of Clinical Pathways

Research in Review

No Difference in Renal Function Decline With ACE inhibitors or ARBs for Diabetes

06/20/2016

JCP Editors

A study comparing the effectivenesses of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) for protecting patients with type 2 diabetes from renal function decline found no...

...

06/20/2016

Journal of Clinical Pathways

Research in Review

Outcomes of Treating ALL With Inotuzumab Ozogamicin

06/14/2016

JCP Editors

A clinical trial assessing the use of inotuzumab ozogamicin in patients with acute lymphoblastic leukemia (ALL) has found that it may be a more effective treatment option than current standard practice. Inotuzumab...

A...

06/14/2016

Journal of Clinical Pathways

New Treatment Improves Response in ALK-Positive NSCLC

06/14/2016

JCP Editors

Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase...

...

06/14/2016

Journal of Clinical Pathways

Daratumumab More Cost Effective for Multiple Myeloma Treatment

06/13/2016

JCP Editors

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical...

...

06/13/2016

Journal of Clinical Pathways

Discontinuing Treatment With Nivolumab Does Not Affect Survival in Patients With Melanoma

06/10/2016

JCP Editors

Discontinuing nivolumab-ipilimumab treatment because of adverse events may not have a detrimental impact on survival among patients with advanced melanoma, according to follow-up from a randomized trial presented at...

...

06/10/2016

Journal of Clinical Pathways

Department

Pembrolizumab Leads to Improved Survival in Patients With Melanoma

06/06/2016

JCP Editors

Patients with advanced melanoma treated with a Programmed cell death protein-1 (PD-1) immune checkpoint inhibitor have longer survival than historically treated patients, according to results from a phase 1 clinical...

...

06/06/2016

Journal of Clinical Pathways

Biomarker-Guided Therapy Leads to Improved Response in Phase 1 Trials

06/05/2016

JCP Editors

Using biomarkers to guide treatment in clinical trials may yield higher response rates than similar drugs not guided by biomarkers, according to an abstract presented at the American Society of Clinical Oncology...

...

06/05/2016

Journal of Clinical Pathways

Tumor Location an Influencer of Survival in Patients With Colorectal Cancer

06/04/2016

JCP Editors

The physical location of a primary tumor may be an indicator of survivor in patients with metastatic colorectal cancer (mCRC), according to results from a large retrospective study presented at the American Society...

The...

06/04/2016

Journal of Clinical Pathways

Research in Review

Integrative Genomic Approach to Cancer Care Leads to More Actionable Variants

06/02/2016

JCP Editors

A genomic approach developed and tested by scientists at the Icahn School of Medicine at Mount Sinai (New York City, NY) helped support decision-making and led to therapeutic recommendations for a group of patients...

A...

06/02/2016

Journal of Clinical Pathways